Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168


Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.

Jaskula E, Dlubek D, Duda D, Bogunia-Kubik K, Mlynarczewska A, Lange A.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1296-305. doi: 10.1016/j.bbmt.2009.06.008. Epub 2009 Aug 8.


The presence of functional CCR5 and EBV reactivation after allogeneic haematopoietic stem cell transplantation.

Bogunia-Kubik K, Jaskula E, Lange A.

Bone Marrow Transplant. 2007 Jul;40(2):145-50. Epub 2007 May 28.


Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ.

Blood. 2002 Jun 15;99(12):4364-9.


Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Löwenberg B, Verdonck LF, Cornelissen JJ.

Blood. 2001 Aug 15;98(4):972-8.


Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.

de Pagter PJ, Schuurman R, Visscher H, de Vos M, Bierings M, van Loon AM, Uiterwaal CS, van Baarle D, Sanders EA, Boelens J.

Biol Blood Marrow Transplant. 2008 Jul;14(7):831-9. doi: 10.1016/j.bbmt.2008.04.016.


The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.

Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E, Tridello G, Varotto S, Alaggio R, Zanesco L, Palù G, Messina C.

Br J Haematol. 2005 Jan;128(2):224-33.


Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation.

Hoshino Y, Kimura H, Tanaka N, Tsuge I, Kudo K, Horibe K, Kato K, Matsuyama T, Kikuta A, Kojima S, Morishima T.

Br J Haematol. 2001 Oct;115(1):105-11.


Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.

Schönberger S, Meisel R, Adams O, Pufal Y, Laws HJ, Enczmann J, Dilloo D.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1428-35. doi: 10.1016/j.bbmt.2010.04.008. Epub 2010 Apr 24.


Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.

Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N, Rickinson AB, Leiner I, Pamer E, Lowenberg B, Cornelissen JJ, Gratama JW.

Blood. 2003 Jun 1;101(11):4290-7. Epub 2003 Feb 6.


Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.

Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B.

J Med Virol. 2008 Mar;80(3):441-54. doi: 10.1002/jmv.21096.


Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.

Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, Scieux C, Devergie A, Socié G, Ribaud P, Adès L, Ferry C, Gluckman E, Charron D, Esperou H, Toubert A, Moins-Teisserenc H.

Transplantation. 2004 Jan 15;77(1):76-84.


A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation.

Cesaro S, Pegoraro A, Tridello G, Calore E, Pillon M, Varotto S, Abate D, Barzon L, Mengoli C, Carli M, Messina C.

Transplantation. 2010 Jun 27;89(12):1533-40. doi: 10.1097/TP.0b013e3181dd6c0a.


Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.

Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R, King B, Macgregor L, Holdsworth R, McCluskey J, Tait BD.

Bone Marrow Transplant. 2006 Apr;37(8):773-9.


Saliva and blood interferon gamma levels and IFNG genotypes in acute graft-versus-host disease.

Resende RG, Correia-Silva JD, Silva TA, Xavier SG, Bittencourt H, Gomez RS, Abreu MH.

Oral Dis. 2012 Nov;18(8):816-22. doi: 10.1111/j.1601-0825.2012.01955.x. Epub 2012 Jul 3.


Supplemental Content

Support Center